Phaseline

Companies › Vanda Pharmaceuticals

Vanda Pharmaceuticals: clinical trials, targets and expected readouts

9 active drug programs in 17 registered trials: 11 Phase 3, 3 Phase 2, 2 Phase 1, 1 Phase 4; Psychiatry, Neurology, Metabolic and endocrine, Other; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
iloperidone
Dopamine D2 receptor antagonist; Serotonin 2a (5-HT2a) receptor antagonist
DRD2, HTR2APhase 4Schizophrenia; HypertensionNov 2026
Tradipitant
Neurokinin 1 receptor antagonist
TACR1Phase 3Idiopathic Gastroparesis; Nausea and Vomiting; Motion SicknessDec 2026
VQW-765–Phase 3Social Anxiety Disorder (SAD)Dec 2026
Tasimelteon
Melatonin receptor agonist
MTNR1A, MTNR1BPhase 3Sleep Wake Disorders; Insomnia DisorderNov 2027
Milsaperidone
5-HT1A receptor partial agonist
HTR1APhase 3Major Depressive Disorder (MDD)Mar 2028
Ponesimod
Sphingosine 1-phosphate receptor Edg-1 agonist
S1PR1Phase 3Moderate-to-severe Chronic Plaque Psoriasis; Ulcerative Colitis (UC)Aug 2028
Trichostatin A (VTR-297)–Phase 2Onychomycosis of Toenail; Relapsed or Refractory Hematologic MalignanciesDec 2027
VSJ-110–Phase 2Dry Eye–
VCA-894A
antisense oligonucleotide targeting IGHMBP2
IGHMBP2Phase 1Charcot Marie Tooth Disease (CMT)Mar 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06701396TasimelteonPhase 3Sleep Wake DisordersNeurologyJun 2025
NCT06836557TradipitantPhase 3Idiopathic GastroparesisMetabolic and endocrineMar 2026
NCT04652882TasimelteonPhase 3Sleep Wake DisordersNeurologySep 2026
NCT07065773Trichostatin A (VTR-297)Phase 2Onychomycosis of ToenailInfectious diseaseSep 2026
NCT07179055VSJ-110Phase 2Dry EyeOphthalmologySep 2026
NCT07090161iloperidonePhase 2HypertensionCardiovascularNov 2026
NCT07446439TradipitantPhase 3Nausea and VomitingMetabolic and endocrineDec 2026
NCT07221578VQW-765Phase 3Social Anxiety Disorder (SAD)PsychiatryDec 2026
NCT07223632VCA-894APhase 1Charcot Marie Tooth Disease (CMT)NeurologyMar 2027
NCT06138613TradipitantPhase 3Motion SicknessOtherSep 2027
NCT06953869TasimelteonPhase 3Insomnia DisorderPsychiatryNov 2027
NCT06961968iloperidonePhase 3SchizophreniaPsychiatryNov 2027
NCT03838926Trichostatin A (VTR-297)Phase 1Relapsed or Refractory Hematologic MalignanciesOncologyDec 2027
NCT06830044MilsaperidonePhase 3Major Depressive Disorder (MDD)PsychiatryMar 2028
NCT07362017PonesimodPhase 3Moderate-to-severe Chronic Plaque PsoriasisImmunologyAug 2028
NCT05648591iloperidonePhase 4SchizophreniaPsychiatryDec 2028
NCT07686081PonesimodPhase 3Ulcerative Colitis (UC)ImmunologyApr 2029

From the company's SEC filings

Cash of $62m on 2026-09-30; operating cash outflow about $147m a year; runway about 5 months at that burn, to Mar 2027; 3 of 6 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 2 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

MTNR1A (1) MTNR1B (1) TACR1 (1) DRD2 (1) HTR2A (1) S1PR1 (1) HTR1A (1) IGHMBP2 (1)

Companies with the same targets

Intra-Cellular Therapies Sichuan Kelun Pharmaceutical Boryung Pharmaceutical Otsuka Novartis Helsinn Healthcare Bayer Prilenia Changchun GeneScience Pharmaceutical LB Pharmaceuticals

Companies built like this

Intra-Cellular Therapies Neurocrine Biosciences VistaGen Therapeutics Alkermes ARS Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.